The med-spa peptide buyer's playbook: GHK-Cu, B-12, lipotropics, and OEM brands

Medical aesthetic clinics and med-spas occupy a specific procurement niche in the peptide market, somewhere between the rigorous regulatory expectations of compounding pharmacy and the looser standards of research-only use. The workhorse SKUs are different, the documentation expectations are different, and the OEM pathway (private-label finished products under the spa's brand) is a major commercial route that compounding-pharmacy buyers don't typically pursue.

This guide covers what med-spa peptide procurement actually looks like.

The workhorse SKUs

Most med-spa peptide procurement concentrates on five or six product categories:

• GHK-Cu (copper tripeptide-1): The dermal-repair workhorse. Used in topical anti-aging serums and in IV/IM injectable preparations. INCI name is Copper Tripeptide-1; see our GHK-Cu formulation guide for the full OEM playbook.
• B-12 (cyanocobalamin or methylcobalamin): The IM-injection mainstay for energy and methylation-support protocols. Solo or in combination with the MIC trio.
• Lipo-C / MIC (methionine + inositol + choline + B-vitamins): The lipotropic injection blend, marketed as "fat-burner shots" or metabolic-support injections.
• L-Carnitine: Fatty-acid-transport supplement, often combined with B-12 and MIC trio in lipotropic protocols.
• Glutathione (GSH): IV antioxidant infusion and dermal-pigmentation protocols (the latter is regulatorily contested in many markets, see below).
• NAD+: IV-infusion longevity-research protocols; the dose is gram-scale, so per-treatment cost is meaningful.

Some clinics extend the catalog with Snap-8, Matrixyl, AHK-Cu for topical formulations; Melanotan I for photoprotection (where regulatorily permitted); and the Wolverine Blend and GLOW Blend for repair-aesthetic crossover protocols.

How med-spa procurement differs from compounding pharmacy procurement

Three operational differences matter:

1. **Documentation depth**: Compounding pharmacy typically requires ≥99.0% HPLC at minimum (with ≥99.5% as an optional upgrade for extra margin), full LAL endotoxin, USP <61>/<62> microbial limits, and 503A / 503B-aligned batch documentation. Med-spa needs ≥99.0% HPLC, microbial limits, and INCI-name documentation for topical-finished-product use. The compounding-pharmacy documentation packet is meaningfully heavier; the analytical floor is the same baseline.

1. **Use-case mix**: Compounding pharmacy almost always means injectable-route compounded preparation. Med-spa mixes injectable (IM lipotropics, IV NAD+ and glutathione) with topical (anti-aging serums and creams). The topical line drives the INCI-name and finished-product regulatory requirements that compounding pharmacy doesn't deal with.

1. **OEM finished-product opportunity**: Med-spa clinics often build a private-label retail line, branded serums and creams sold to clinic patients between visits. This is a meaningfully different procurement workflow than the in-clinic injectable supply.

The OEM finished-product pathway

Building a private-label cosmetic peptide brand involves several stages beyond bulk peptide procurement:

• Formulation development: The bulk peptide is one ingredient in a finished serum or cream. The carrier, preservation system, packaging, and stability profile of the finished product all matter for the consumer experience and the regulatory pathway.
• INCI naming verification: Every cosmetic ingredient has a standardized INCI (International Nomenclature of Cosmetic Ingredients) name that must be used in the finished-product ingredient list. GHK-Cu is "Copper Tripeptide-1"; Snap-8 is "Acetyl Octapeptide-3"; Matrixyl is "Palmitoyl Pentapeptide-4". Mis-named ingredients can produce regulatory action.
• Stability testing: Real-time at 25°C/60% RH and accelerated at 40°C/75% RH, typically over 6 months for product launch and 24 months for shelf-life claims.
• Safety assessment and challenge testing: Required for EU CPNP notification and analogous registries in other markets.
• Manufacturing under cGMP-equivalent conditions: For brands selling internationally, finished-product manufacturing should be GMP-aligned even where not strictly required by the destination market.

Vialdyne's OEM service covers all stages, see our OEM workflow guide for the end-to-end process. Typical timeline from signed brief to first commercial shipment is 8-14 weeks for a finished cosmetic product.

Regulatory landscape, the contested zones

Several common med-spa peptide protocols sit in regulatorily contested territory. Buyers should understand the contestation rather than treating these as routine:

• Tirzepatide and Semaglutide compounding: FDA's evolving position on whether compounding pharmacies can prepare these molecules under shortage frameworks affects med-spa supply. See our GLP-1 class comparison for the broader pharmacology context.
• Glutathione IV for dermal pigmentation: The FDA has issued warnings against this specific use case despite glutathione's approved status for other indications. Several countries have banned IV glutathione for skin-lightening explicitly.
• Korean-origin lipolytic injectables (Lemon Bottle, Aqualyx-class): Approved or tolerated in several Asian markets, off-label or grey-market in the UK/EU, prohibited in the US. See the Lemon Bottle product page for the jurisdictional matrix.
• Melanotan II: Heavily regulated or banned for direct human use in UK, Australia, EU, Canada, research-use only in most major markets.

Clinics operating in jurisdictions where these protocols are contested should obtain clear regulatory advisory before procurement rather than assuming the catalog item is automatically appropriate for their destination market.

What to ask your peptide supplier as a med-spa buyer

Beyond the universal supplier-vetting checks (see our supplier qualification guide), med-spa-specific questions:

• INCI naming on every shipment SDS (for any topical-route peptide)
• Cosmetic-grade specification sheet (separate from research-grade COA)
• Stability data on finished-formulation carrier systems (if planning OEM)
• Regulatory advisory specific to the destination market for any contested peptide
• OEM private-label development capability with realistic timeline and MOQ ranges

Vialdyne's regulatory team supports all of these. Quote stage is the right point to specify the use case mix (injectable IV/IM vs topical finished product vs both) so the documentation scope matches the actual procurement profile.